Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Beta: 1.0073 (As of Jun. 26, 2026)


SHSE:600276 Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
86 GF Score
Price ¥48.67
GF Value ¥60.34
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Beta?

Jiangsu Hengrui Pharmaceuticals Co SHSE:600276 -2.74% 86 Beta is 1.0073 as of Jun. 26, 2026. GuruFocus rates SHSE:600276 with a GF Score™ of 86/100 and a GF Value™ of ¥60.34 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Jiangsu Hengrui Pharmaceuticals Co's Beta is 1.0073.


Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Jiangsu Hengrui Pharmaceuticals Co Beta Related Terms


Jiangsu Hengrui Pharmaceuticals Co Beta Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Beta Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.98 0.95 1.10 1.24 1.20

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 0.90 0.96 1.20 1.09

SHSE:600276 vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Beta distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Beta falls into.


SHSE:600276
86GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.0073 mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Beta of 1.0073 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jiangsu Hengrui Pharmaceuticals Co and its competitors.
Is Jiangsu Hengrui Pharmaceuticals Co's Beta too high?
Jiangsu Hengrui Pharmaceuticals Co's current Beta is 1.0073. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Beta compare to ZTS and UTHR?
Jiangsu Hengrui Pharmaceuticals Co's Beta of 1.0073 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jiangsu Hengrui Pharmaceuticals Co and its competitors. Jiangsu Hengrui Pharmaceuticals Co's current Beta is 1.0073. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.34, compared to a current price of ¥48.67 — trading 19.3% below its estimated fair value. The current Beta is 1.0073. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Beta is 1.0073 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥48.67 is trading 19.3% below its estimated GF Value™ of ¥60.34. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for SHSE:600276:

  • Beta: 1.0073
  • GF Value™: ¥60.34 vs. price of ¥48.67 (19.3% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score

Get the complete analysis for SHSE:600276

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥48.67
Price
¥60.34
GF Value